药械

订阅

MedSci主页 / 所有栏目 / 药械

默沙东丙肝鸡尾酒MK-5172/MK-8742初治群体治愈率近100%

2014-04-11 tomato 生物谷

新药FDA
关注

默沙东（Merck & Co）4月10日公布了一项正在开展的II期研究（C-WORTHY Study）的额外数据。对初治非肝硬化患者组开展的一项中期分析表明，接受为期12周的MK-5127/MK-8742方案（联合利巴韦林RBV及无RBV）治疗后，MK-5127/MK-8742（无RBV）治疗组有98%（42/43）的患者取得持续病毒学应答（SVR），MK-5127/MK-8742+RBV

默沙东（Merck & Co）4月10日公布了一项正在开展的II期研究（C-WORTHY Study）的额外数据。对初治非肝硬化患者组开展的一项中期分析表明，接受为期12周的MK-5127/MK-8742方案（联合利巴韦林RBV及无RBV）治疗后，MK-5127/MK-8742（无RBV）治疗组有98%（42/43）的患者取得持续病毒学应答（SVR），MK-5127/MK-8742+RBV治疗组为94%（75/80）。这些数据连同8周方案的数据已提交至第49届欧洲肝脏研究协会年会（EASL 2014-49th）。

MK-5172和MK-8742均属于非常有前途的新一类抗病毒药物。MK-5172是一种实验性HCV NS3/4A蛋白酶抑制剂，MK-8742则是一种实验性HCV NS5A复制复合体抑制剂。此前，FDA于2013年10月授予MK-5172/MK-8742全口服方案突破性疗法认定。

慢性丙型肝炎是默沙东研发的优先重点。目前，该公司正在一个广泛的临床项目中评价MK-5172和MK-8742，包括多种HCV基因型感染初治患者、治疗失败的患者、以及其他重要的HCV亚群，如肝硬化和HCV/HIV合并感染。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    不错的文章，学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-10-15 cenghis

    #治愈率#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2015-03-21 xjy13

    #群体#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 yese

    #默沙东#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 qblt

    #鸡尾酒#

    0

相关资讯

FDA授予诺华脑膜炎疫苗Bexsero突破性疗法认定

诺华（Novartis）4月7日宣布，FDA已授予B型脑膜炎球菌疫苗Bexsero突破性疗法认定。目前，Bexsero已获欧盟、加拿大、澳大利亚批准，用于年龄在2个月以上的人群。Bexsero是首个也是唯一一个宽覆盖范围的B型脑膜炎球菌疫苗，用于帮助保护所有年龄段人群预防B型脑膜炎，包括婴儿。 诺华计划于2014年第二季度向FDA提交Bexsero的监管文件。这是诺华获得的第4个突破性疗法认定，

百时美丙肝鸡尾酒疗法DCV/ASV III期治愈率达90%

百时美施贵宝（BMS）4月10日公布了丙肝鸡尾酒疗法（daclatasvir+asunaprevir，即DCV+ASV）一项国际性III期研究HALLMARK-DUAL的数据。DCV+ASV是一种实验性全口服、无干扰素、无利巴韦林丙肝治疗方案。该项研究在基因型1b丙型肝炎病毒（HCV）感染者中开展，数据表明，接受DCV+ASV方案治疗后，初治患者组有90%的患者实现SVR12（完成治疗后12周的持

以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展 能延长晚期乳癌患者生命

肿瘤新药以及新靶点药物研究成为热点领域。其中针对CDK4/6的乳腺癌新药成为新的竞争焦点。以辉瑞，礼来和诺华三家公司为代表的新药palbociclib，LY2835219和LEE011引发广泛关注。今年的美国癌症研究学会年会上，礼来公司的CDK4/6抑制剂类药物LY2835219引起了业界的广泛关注。礼来公司表示，目前研究人员正在进行这种药物的三期临床研究实验设计，相信很快就能进入三期研究阶段。近

勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准

勃林格殷格翰（Boehringer Ingelheim）4月7日宣布，FDA已批准Pradaxa（dabigatran，达比加群酯）用于已接受5-10天肠外抗凝剂（parenteral anticoagulant）的患者，治疗深静脉血栓（DVT）和肺栓塞（PE），以及用于既往已治疗过的患者，降低DVT和PE复发的风险。 深静脉血栓（DVT）和肺栓塞（PE）统称为静脉血栓栓塞（VTE），是继冠状动

Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀

Puma生物技术公司4月7日公布了抗癌药neratinib（来那替尼）一项II期研究（I-SPY 2）的数据。该项研究在193例术前新诊具有高复发风险（根据前期肿瘤属性判断，包括肿瘤大小、激素受体HR状态、HER2状态、MammaPrint-70基因指纹检测）的2阶段或更晚阶段（肿瘤至少2.5cm）的乳腺癌患者开展，调查了将neratinib添加至标准化疗用于新辅助治疗（neoadjuvant s

安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期

安进（Amgen）4月5日公布了实验性溶瘤免疫疗法talimogene laherparepvec（T-Vec）黑色素瘤关键性III期研究的总生存期（OS）初步分析数据。该项研究在可注射未切除IIIB、IIIC、IV期黑色素瘤（melanoma）患者中开展，将T-Vec疗法与皮下注射粒细胞-巨噬细胞集落刺激因子（GM-CSF）疗法进行了对比。数据表明，该项研究达到了持久反应率（DRR）的主要终点（